GMAX Bio Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 74

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

GMAX Bio General Information

Description

Developer of therapeutic antibodies designed for cardiovascular diseases, metabolic disorders, and cancer. The company's technology utilizes an in-house antibody development platform, antibody humanization, and engineering, providing healthcare providers with monoclonal antibodies and fusion proteins for the treatment of diabetes, obesity, and heart failure.

Contact Information

Formerly Known As
Hangzhou Hongyun Huaning Biomedical Engineering
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building 2
  • Number 288 Qiuyi Road, Binjiang District
  • Hangzhou, Zhejiang 310050
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3rd Floor, Building 2
  • Number 288 Qiuyi Road, Binjiang District
  • Hangzhou, Zhejiang 310050
  • China
+86 0571

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GMAX Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 06-Jul-2026 Completed Generating Revenue
6. Later Stage VC 26-Jun-2024 Completed Generating Revenue
5. Later Stage VC (Series C) 05-Mar-2021 Completed Generating Revenue
4. Secondary Transaction - Private 18-Apr-2018 Completed Generating Revenue
3. Later Stage VC (Series B) 27-Nov-2017 Completed Clinical Trials - General
2. Later Stage VC 12-Dec-2016 $4.28M $11.3M Completed Clinical Trials - General
1. Early Stage VC (Series A) 01-Dec-2014 $7.01M $7.01M Completed Pre-Clinical Trials
To view GMAX Bio’s complete valuation and funding history, request access »

GMAX Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic antibodies designed for cardiovascular diseases, metabolic disorders, and cancer. The company's
Drug Discovery
Hangzhou, China
74 As of 2024

Beijing, China
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GMAX Bio Competitors (28)

One of GMAX Bio’s 28 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mabworks Biotech Venture Capital-Backed Beijing, China
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Gracell Formerly VC-backed Shanghai, China
CureGenetics Venture Capital-Backed Suzhou, China
Adagene Formerly VC-backed Suzhou, China
You’re viewing 5 of 28 competitors. Get the full list »

GMAX Bio Patents

GMAX Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026021575-A1 Pharmaceutically stable solution formulation with gipr antibody fusion protein and use thereof Pending 26-Jul-2024
AU-2023337288-A1 Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof Pending 08-Sep-2022
EP-4585617-A1 Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof Pending 08-Sep-2022
EP-4585617-A4 Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof Pending 08-Sep-2022
US-20260356962-A1 Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof Pending 08-Sep-2022 C07K16/2869
To view GMAX Bio’s complete patent history, request access »

GMAX Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GMAX Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brill Capital Family Office Minority
China Merchants Group Holding Company Minority
Cowin Capital Venture Capital Minority
Dongguan Group Corporation Minority
Fellow Partners Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

GMAX Bio Investments (1)

GMAX Bio’s most recent deal was a Early Stage VC with Teligene. The deal was made on 01-Apr-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Teligene 01-Apr-2012 Early Stage VC Pharmaceuticals
To view GMAX Bio’s complete investments history, request access »

GMAX Bio FAQs

  • When was GMAX Bio founded?

    GMAX Bio was founded in 2010.

  • Where is GMAX Bio headquartered?

    GMAX Bio is headquartered in Hangzhou, China.

  • What is the size of GMAX Bio?

    GMAX Bio has 74 total employees.

  • What industry is GMAX Bio in?

    GMAX Bio’s primary industry is Drug Discovery.

  • Is GMAX Bio a private or public company?

    GMAX Bio is a Private company.

  • What is GMAX Bio’s current revenue?

    The current revenue for GMAX Bio is .

  • How much funding has GMAX Bio raised over time?

    GMAX Bio has raised $94.3M.

  • Who are GMAX Bio’s investors?

    Brill Capital, China Merchants Group, Cowin Capital, Dongguan Group, and Fellow Partners are 5 of 6 investors who have invested in GMAX Bio.

  • Who are GMAX Bio’s competitors?

    Mabworks Biotech, CytomX Therapeutics, Gracell, CureGenetics, and Adagene are some of the 28 competitors of GMAX Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process